IL-1β signaling on dendritic cells expands tumor-specific T cells to overcome immune checkpoint blockade resistance.
Abstract
Immune checkpoint blockade (ICB) therapy benefits only a subset of patients, and the role of non-T cells in ICB responses remains unclear. IL-1β has been reported to conduct controversial roles in antitumor immunity and ICB responsiveness. Here we show that IL-1β signaling is indispensable for the response to ICB therapy and for intratumoral tumor-specific CD8+ T cells. We hypothesized that ICB resistance is attributed to limited IL-1β inside tumor microenvironment (TME). We engineered mesenchymal stromal cells for the tumor-targeted inducible production of IL-1β-Fc (IL1βFc-EMSC) to study how this cytokine induces antitumor immunity inside the TME. Mechanistically, IL1βFc-EMSC treatment expands CD8+ T cells including Tcf1+PD1+ progenitor exhausted CD8+ T cells (Tpex) in the TME and enhances tumor-specific CD8+ T cell activation. MyD88 signaling in dendritic cells (DCs) by IL-1β might trigger type I IFN that are essential for intratumoral CD8+ T cell restimulation and systemic antitumor responses to eradicate both primary and distal tumors. Moreover, IL1βFc-EMSC treatment induced TIL reinvigoration overcomes ICB resistance in advanced tumors. Clinically, we uncovered a significant association between the formation of a spatially organized IL-1β-cDC1-Tpex axis and ICB responsiveness. Overall, tumor targeting IL-1β reshapes the TME by bridging innate and adaptive immunity to overcome ICB resistance.